Heat Biologics Stock Price - HTBX

-0.0099 (-1.98%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Heat Biologics Inc HTBX NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 0.50 0.4895 0.55 0.5264 0.50 00:00:05
Bid Price Ask Price Spread Spread % News
0.48 0.5653 0.0853 15.09% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
6,336 3,650,665 $ 0.5091497 $ 1,858,735 25,383,428 0.1811 - 1.27
Last Trade Time Type Quantity Stock Price Currency
19:59:57 formt 1,337 $ 0.4901 USD

Heat Biologics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 39.69M 79.38M $ -15.73M -0.59 - 75.62M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 10.00 4.70%

more financials information »

Heat Biologics News

Loading Messages....

Latest HTBX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HTBX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.5990.63250.48950.5457743,750,859-0.099-16.53%
1 Month0.8250.980.470.629354612,125,837-0.325-39.39%
3 Months0.451.250.18110.708112913,535,5830.0511.11%
6 Months0.471.250.18110.70135236,329,8200.036.38%
1 Year1.211.270.18110.70403023,337,940-0.71-58.68%
3 Years8.608.800.18111.331,543,473-8.10-94.19%
5 Years63.1086.500.18114.761,264,044-62.60-99.21%

Heat Biologics Description

Heat Biologics Inc is a US-based immuno-oncology company. It is engaged in developing therapies that activate a patient's immune system against cancer utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT), form the basis of its product candidates. Through ImPACT, it developed product candidates consisting of live, genetically-modified, irradiated human cancer cells that secrete tumor-associated antigens together with an immune response stimulator called gp96. Through ComPACT, the firm engineered product candidates that incorporate ligand fusion proteins targeting co-stimulatory receptors into the gp96-Ig expression vector.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.